VC Deals Analysis: Quarter-Billion Round Hikes September Takings To Five-Year High
Executive Summary
September benefitted from two nine-figure venture financing rounds, including a $250m round by consumer genetic test service provider 23andme. These bumper deals significantly boost the total takings in 2017 so far to the extent that the year looks likely to beat 2016.
You may also be interested in...
Exec Chat: Illumina Enters Second Wave Of Growth As Genomics Demand Swells
Illumina is capitalizing on the inexorable rise of genomics, as governments around the world step up their focus on precision medicine and deliver higher quality, yet more cost-effective, health care to the population. Paula Dowdy, who joined the firm as head of its EMEA commercial operations a year ago, believes that Europe will lead the charge in making genomics a core component of health care, and the growth story of the company – and the genomics sector as a whole – is far from over. She speaks to Medtech Insight about the parallels between the tech industry, where she had garnered over 20 years' commercial experience, and the genomics sector and gives her perspectives on Illumina's strategies for sustaining the growth trajectory of its EMEA business.
VC Deals Analysis: From Famine To Feast, 2017 Bloats With May Haul
The venture financing climate has been somewhat dull so far this year but the investment activity levels enjoyed a much-needed boost in May. The month's haul of transactions not only brought in the quantity – with the highest deal volume to date – but also quality, high-value rounds.
VC Deals Analysis: Big Boost From Bumper Round
It had been a slow start to the year but one unusually large financing round from cancer diagnostics company Grail means the first quarter of 2017 has now outpaced the performance from any in the previous four years.